Bacteremia

You suspect your patient has a bloodstream infection

You’re balancing the need to find the source with the urgency of treatment decisions and may have little to go on beyond positive blood cultures.

You need to know what you’re dealing with and what options you have to treat with as quickly and safely as possible. That’s where we come in. We’ll help you ID that little bugger and determine antimicrobial susceptibility results in about 7 hours directly from positive blood cultures.

Get faster results direct from positive blood cultures

Bacteremia, a frequent cause of sepsis and septic shock, continues to be a major cause of serious illness and death despite major advances in medicine.1,2 Blood is a sterile site, so when blood cultures turn positive, antimicrobials are almost always administered empirically.

If delayed, the risk of a patient progressing to sepsis or septic shock increase. This urgency combined with increasing rates of antimicrobial resistance has led many to resort to very broad-spectrum initial coverage and an aversion to change that therapy until antimicrobial susceptibility is determined – a process that can take days.

Earlier optimization of antimicrobial therapy improves patient outcomes

The Accelerate Pheno™ system delivers phenotypic antibiotic susceptibility results along with organism identification directly from positive blood cultures — critical information to select the best drug, for the specific pathogen, at the MIC-driven dose ~ 40 hours faster than current methods used in most labs today.3

Hospitals nationwide face interrelated challenges in the care of patients with bacteremia. Downward reimbursement pressures, the increasing incidence of MDR (multi-drug resistant) infections necessitating costly isolation procedures, and delays in actionable diagnostic results limit options for patient treatment.

When you get susceptibility data 1-2 days earlier than usual, you can act – you can adjust treatment, maximizing the benefits of a tailored antimicrobial approach in the safest way possible for your patient.

View Outcomes Data

View Patient Cases

Bacteremia is a common and serious problem affecting 15% of critically ill patients 4

  • Bloodstream infections (BSIs) and, bacteremia specifically, are associated with threefold higher mortality4,5
  • 1 in 6 central-line associated bloodstream infections was caused by urgent or serious antibiotic-resistant threats6
  • Bacteremia has been associated with prolonged hospital stays of 2-3 weeks with $25,000 to $40,000 in additional costs7,8

1  Moreno R, et al. Incidence of sepsis in hospitalized patients. Curr Infect Dis Rep. 2006;8:346–50.
2  Goto M, et al. Overall burden of bloodstream infection and nosocomial bloodstream infection in North America and Europe. Clin Microbiol Infect. 2013;19:501–9.
3  Banerjee R, et al. Randomized trial evaluating clinical impact of RAPid IDentification and Susceptibility testing for Gram Negative bacteremia (RAPIDS-GN), Clin Infect Dis. 2020
4 Vincent JL, et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA. 2009;302:2323–9.
5 Renaud B, Brun-Buisson C. Outcomes of primary and catheter-related bacteremia. A cohort and case-control study in critically ill patients. Am J Respir Crit Care Med. 2001;163:1584–90.
6 CDC Vital Signs, March 2016. https://www.cdc.gov/vitalsigns/pdf/2016-03-vitalsigns.pdf
7 Pittet D, Tarara D, Wenzel RP. Nosocomial bloodstream infection in critically ill patients. Excess length of stay, extra costs, and attributable mortality. JAMA. 1994;271:1598–601.
8 Laupland KB, Lee H, Gregson DB, Manns BJ. Cost of intensive care unit-acquired bloodstream infections. J Hosp Infect. 2006;63:124–32.

See Results
View Outcomes Data
See the difference
View Stories